Wedbush Starts Bluebird Bio (BLUE) at Outperform

July 15, 2013 11:01 AM EDT Send to a Friend
Get Alerts BLUE Hot Sheet
Price: $42.71 +3.44%

Rating Summary:
    8 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 29 | Down: 43 | New: 4
Trade BLUE Now!
Join SI Premium – FREE
Wedbush initiated coverage on Bluebird Bio (NASDAQ: BLUE) with an Outperform rating and a price target of $32.25.

"We view bluebird as a leader in gene therapy, with potential broad applicability of its transformative technology in rare diseases and oncology," said analyst David M. Nierengarten. "Bluebird's gene therapy platform could provide lifelong cures of genetic diseases with a single procedure, and is potentially applicable to a broad range of inherited diseases."

For an analyst ratings summary and ratings history on Bluebird Bio click here. For more ratings news on Bluebird Bio click here.

Shares of Bluebird Bio closed at $30.65 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS View, New Coverage

Add Your Comment